Observation of the Effect of Combination Therapy with Camrelizumab and Chemotherapy on advanced non-small-cell Lung Cancer and its Impact on Tumor Markers
Objective To analyze the therapeutic effect of combination therapy with Camrelizumab and chemotherapy on advanced non-small-cell lung cancer,and to explore the impact of this combination therapy on tumor markers.Methods A total of 68 patients with advanced non-small-cell lung cancer from March 2022 to October 2023 were selected as study samples.According to the willingness of patients to receive immunotherapy,34 patients who did not accept immunotherapy were included in the control group.Cisplatin and carboplatin chemotherapy was given,and 34 patients who received immunotherapy were included in the study group,Camrelizumab was used in combination with conventional chemotherapy.The effective rate of the two groups was compared,the levels of tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1),carbohydrate antigen 50(CA50)],immune indicators[immunoglobulin A(IgA),immunoglobulin G(IgG),immunoglobulin M(IgM)],and the occurrence of adverse reactions were compared before and after treatment.Results The effective rate of treatment in the study group(82.35%)was higher than that in the control group(58.82%),and the difference was statistically significant(P＜0.05);There was no statistically significant difference in the CEA,CYFRA21-1,and CA50 values between the two groups before treatment(P＞0.05).After treatment,the CEA,CYFRA21-1,and CA50 values in both groups were lower than those before treatment,and the study group was lower than the control group,with statistical significance(P＜0.05);There was no statistically significant difference in the IgA,IgG,and IgM values between the two groups before treatment(P＞0.05).After treatment,the IgA,IgG,and IgM values in both groups were higher than those before treatment,and the study group had higher values than the control group,with statistical significance(P＜0.05);The incidence of adverse reactions during medication treatment in the study group(20.59%)was not statistically significant compared to the control group(14.71%)(P＞0.05).Conclusion The combination therapy of Camrelizumab and chemotherapy for advanced non-small-cell lung cancer can achieve ideal therapeutic effects.Compared with conventional clinical treatment,this combination therapy has lower levels of tumor markers,better immune function recovery,and guaranteed safety,it is worthy of application.
Camrelizumabadvanced non-small-cell lung cancertumor markersimmunologic function
国家科技期刊平台
NSTL
万方数据
